These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1840246)

  • 1. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation.
    Fieseler HG; Armstrong VW; Wieland E; Thiery J; Schütz E; Walli AK; Seidel D
    Clin Chim Acta; 1991 Dec; 204(1-3):291-300. PubMed ID: 1840246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a.
    Hunninghake DB; Stein EA; Mellies MJ
    J Clin Pharmacol; 1993 Jun; 33(6):574-80. PubMed ID: 8366183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus.
    Umeda F; Watanabe J; Inoue K; Hisatomi A; Mimura K; Yamauchi T; Sako Y; Kunisaki M; Tajiri Y; Nawata H
    Endocrinol Jpn; 1992 Feb; 39(1):45-50. PubMed ID: 1535040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
    Branchi A; Rovellini A; Fiorenza AM; Sommariva D
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
    Richter WO; Jacob BG; Schwandt P
    Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of cholesterol-lowering on plasma membrane lipids and function.
    Lijnen P; Echevaría-Vázquez D; Petrov V
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pravastatin effects on lipoproteins, Lp (a), apo B and apo A-1 in patients with primary hypercholesterolemia].
    Novazzi JP; Fonseca FA; Feres MC; da Silva RC; Lima JC; Martinez TL
    Arq Bras Cardiol; 1994 Jun; 62(6):395-8. PubMed ID: 7826229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between apolipoprotein B-100 and low-density lipoprotein cholesterol after treatment with an HMG CoA reductase inhibitor.
    Levinson SS; Blevins RD; Smith MP; Rubinfire M; Maciejko JJ
    Am J Clin Pathol; 1989 Oct; 92(4):479-83. PubMed ID: 2508466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration.
    Klausen IC; Gerdes LU; Meinertz H; Hansen FA; Faergeman O
    Eur J Clin Invest; 1993 Apr; 23(4):240-5. PubMed ID: 8500516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term administration of pravastatin reduces serum lipoprotein(a) levels.
    Horimoto M; Hasegawa A; Takenaka T; Fujiwara M; Inoue H; Igarashi K
    Int J Clin Pharmacol Ther; 2003 Nov; 41(11):524-30. PubMed ID: 14620949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
    Lahoz C; Peña R; Mostaza JM; Laguna F; García-Iglesias MF; Taboada M; Pintó X
    Metabolism; 2005 Jun; 54(6):741-7. PubMed ID: 15931608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin.
    Lijnen P; Celis H; Desager JP; Fagard R
    J Hum Hypertens; 1995 Jul; 9(7):557-64. PubMed ID: 7562885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
    Tobert JA
    Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pravastatin sodium, a new HMG-CoA reductase inhibitor.
    Raasch RH
    DICP; 1991 Apr; 25(4):388-94. PubMed ID: 1926908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.